In this section
Introduction
Patients with platinum sensitive relapsed ovarian cancer and germline or somatic mutations in BRCA1/2 may benefit from treatment with the poly ADP ribose polymerase (PARP) inhibitor Lynparza (Olaparib). BRCA1/2 mutation screening in blood or FFPE tissue can identify patients with BRCA1/2 mutations who may benefit from targeted therapy.
Please refer to the National Genomic Test Directory for Cancer here.
Reporting times
- Ovarian panel (FFPE) 21 calendar days
- Ovarian panel (Germline) 42 calendar days
Please refer to our Sample Requirements section before sending any samples to us for testing.